With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Using AI to improve oncology care and find the right clinical trials for patients.

Doing more to ease the challenges of antibody drug conjugate manufacturing.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

How understanding and manipulating senescence dynamics could optimize cancer therapies and improve patient outcomes.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.